IQVIA and Medera partner to advance cardiac gene therapy trials

IQVIA and Medera have announced a strategic collaboration to accelerate the clinical development of cardiac gene therapies and expand use of Medera's human-based drug discovery tools, the companies said on 4 August 2026.

The partnership pairs IQVIA's global trial infrastructure with two platforms operated by Medera: Sardocor, its clinical-stage arm advancing AAV-based gene therapies for heart failure and Duchenne muscular dystrophy-associated cardiomyopathy, and Novoheart, its preclinical subsidiary built around a proprietary engineered human cardiac tissue system known as the mini-Heart.

The deal

Under the arrangement, IQVIA will support patient recruitment, data management and regulatory filings for Sardocor's FDA-cleared, first-in-human gene therapy programmes. The two companies also plan to pursue expedited FDA designations, building on Novoheart's existing IND and Fast Track successes, where the mini-Heart platform has already been used to generate preclinical evidence acceptable to regulators.

Ronald Li, co-founder, chairman and chief executive of Medera, said the collaboration would "expand our reach, while reinforcing the scientific and regulatory momentum around human-based drug discovery and cardiac gene therapy innovation." Financial terms were not disclosed, and the announcement did not specify which Sardocor trials will be prioritised first under the agreement.

Medera's pipeline spans heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF) and Duchenne muscular dystrophy cardiomyopathy, making it one of the broader cardiac gene therapy pipelines currently in clinical development.

Market context

Cardiac gene therapy is a sector still finding its commercial footing. BioMarin, Pfizer and Sarepta have navigated mixed regulatory outcomes in adjacent rare cardiovascular and neuromuscular gene therapy programmes, underscoring how demanding the path to approval remains even for well-resourced sponsors. For a clinical-stage company such as Medera, access to IQVIA's patient recruitment networks and regulatory affairs expertise could meaningfully de-risk enrolment timelines, which have historically been a bottleneck in rare cardiovascular studies.

The Novoheart element of the deal is also worth watching in a wider policy context. The FDA Modernization Act 2.0, enacted in late 2022, removed the mandatory requirement for animal testing prior to IND submission, opening the door for human organoid and microphysiological systems to take a larger role in pre-clinical packages. Medera is among a small number of companies actively positioning such platforms as commercially available services to other drug developers, not just as internal tools. If Novoheart data continue to be accepted by the FDA in support of IND applications, the platform could attract interest from sponsors seeking to reduce animal study timelines and costs under the evolving regulatory framework.

IQVIA, which employs approximately 94,000 people across more than 100 countries, has made a series of partnerships with clinical-stage biotechs in recent years as competition for trial execution mandates intensifies. For Medera, the collaboration provides a path to scale without the cost of building an equivalent infrastructure in-house.